Kriger-Sharabi Ofra, Malnick Stephen D H, Fisher David
Institute of Gastroenterology, Assuta Medical Center, Ashdod 7747629, Israel.
Department of Internal Medicine, Kaplan Medical Center, Rehovot 76100, Israel.
World J Clin Cases. 2023 Jul 26;11(21):4975-4988. doi: 10.12998/wjcc.v11.i21.4975.
The gut microbiota has important functions in the regulation of normal body functions. Alterations of the microbiota are being increasingly linked to various disease states. The microbiome has been manipulated the administration of stool from animals or humans, for more than 1000 years. Currently, fecal microbiota transplantation can be performed endoscopic administration of fecal matter to the duodenum or colon or capsules of lyophilized stools. More recently fecal microbial transplantation has been shown to be very effective for recurrent infection (CDI). In addition there is some evidence of efficacy in the metabolic syndrome and its hepatic manifestation, metabolic associated fatty liver disease (MAFLD), irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). We review the current literature regarding the microbiome and the pathogenesis and treatment of CDI, MAFLD, IBS and IBD.
肠道微生物群在调节正常身体功能方面具有重要作用。微生物群的改变与各种疾病状态的联系日益密切。在1000多年的时间里，人们一直通过施用动物或人类粪便来操控微生物组。目前，粪便微生物群移植可以通过将粪便物质经内镜注入十二指肠或结肠来进行，也可以通过冻干粪便胶囊来进行。最近，粪便微生物移植已被证明对复发性艰难梭菌感染（CDI）非常有效。此外，有一些证据表明其在代谢综合征及其肝脏表现即代谢相关脂肪性肝病（MAFLD）、肠易激综合征（IBS）和炎症性肠病（IBD）方面具有疗效。我们综述了关于微生物组以及CDI、MAFLD、IBS和IBD的发病机制与治疗的当前文献。
